Brunetti Marta, Agostini Antonio, Davidson Ben, Tropé Claes G, Heim Sverre, Panagopoulos Ioannis, Micci Francesca
Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Centre for Cancer Biomedicine, University of Oslo, Oslo, Norway.
Oncotarget. 2017 Mar 7;8(10):16843-16850. doi: 10.18632/oncotarget.15167.
Juxtaposition of two different genes or gene parts due to chromosomal rearrangement is a well-known neoplasia-associated pathogenetic mechanism. The detection and characterization of such tumorigenic fusions is of great importance both research-wise, diagnostically because they may be specific for distinct tumor entities, and because they may serve as therapeutic targets for antioncogenic drugs that interact directly with the molecular changes responsible for neoplastic transformation.At present, more than 10,000 fusion transcripts have been reported in different types of neoplasia, with one tenth of them being identified in squamous cell carcinomas (SCC) of different locations. No recurrent fusion gene has to date been identified in SCC of the vulva.We performed high-throughput paired-end RNA-sequencing of 12 vulvar SCC and found two recurrent fusions with the STIP1-CREB3L1 and ZDHHC5-GPR137 being present in two tumors each. The transcripts were detected only in the tumor samples, not in normal vulvar tissue from healthy donors used as control. The CREB3L1 and ZDHHC5 genes encode proteins involved in transcription suggesting that the chimeras may alter downstream events in their respective pathways. Expression analysis of the CREB3L1 gene showed the presence of two distinct groups of tumors, one having fusion and downregulation of the gene and the other showing upregulation of CREB3L1.
由于染色体重排导致两个不同基因或基因部分并置是一种众所周知的与肿瘤形成相关的致病机制。此类致瘤性融合的检测和特征分析在研究方面以及诊断方面都非常重要,因为它们可能对不同的肿瘤实体具有特异性,还因为它们可能作为抗癌药物的治疗靶点,这些药物直接与导致肿瘤转化的分子变化相互作用。目前,在不同类型的肿瘤中已报道了超过10000种融合转录本,其中十分之一在不同部位的鳞状细胞癌(SCC)中被鉴定出来。迄今为止,在外阴鳞状细胞癌中尚未发现复发性融合基因。我们对12例外阴鳞状细胞癌进行了高通量双末端RNA测序,发现了两种复发性融合,其中STIP1-CREB3L1和ZDHHC5-GPR137分别在两个肿瘤中出现。这些转录本仅在肿瘤样本中检测到,在用作对照的健康供体的正常外阴组织中未检测到。CREB3L1和ZDHHC5基因编码参与转录的蛋白质,这表明嵌合体可能会改变其各自途径中的下游事件。CREB3L1基因的表达分析显示存在两组不同的肿瘤,一组基因有融合且下调,另一组CREB3L1上调。